David Giannandrea

David Giannandrea

Auto-generated profile, based on publicly available information

David Giannandrea

Neurology Unit, Department of Specialist Medicine, USL Umbria 1 North Area, Gubbio and Gualdo Tadino Hospital, Gubbio, Italy

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in The Lancet
Verified
Journal Article
Open access
YHYining Huang
Yining Huang
XCXiaoying Chen
Xiaoying Chen
HAHisatomi Arima
Hisatomi Arima
GCGuofang Chen
Guofang Chen
QLQiang Li
Qiang Li
DVD. Ngo Van
D. Ngo Van
Systolic blood pressure of more than 185 mm Hg is a contraindication to thrombolytic treatment with intravenous alteplase in patients with acute ischaemic stroke, but the target systolic blood pressure for optimal outcome is uncertain. We assessed intensive blood pressure lowering compared with guideline-recommended blood pressure lowering in patients treated with alteplase for acute ischaemic stroke. We did an international, partial-factorial, open-label, blinded-endpoint trial of thrombolysis-eligible patients (age ≥18 years) with acute ischaemic stroke and systolic blood pressure 150 mm Hg or more, who were screened at 110 sites in 15 countries. Eligible patients were randomly assigned (1:1, by means of a central, web-based program) within 6 h of stroke onset to receive intensive (target systolic blood pressure 130-140 mm Hg within 1 h) or guideline (target systolic blood pressure <180 mm Hg) blood pressure lowering treatment over 72 h. The primary outcome was functional status at 90 days measured by shift in modified Rankin scale scores, analysed with unadjusted ordinal logistic regression. The key safety outcome was any intracranial haemorrhage. Primary and safety outcome assessments were done in a blinded manner. Analyses were done on intention-to-treat basis. This trial is registered with ClinicalTrials.gov, number NCT01422616. Between March 3, 2012, and April 30, 2018, 2227 patients were randomly allocated to treatment groups. After exclusion of 31 patients because of missing consent or mistaken or duplicate randomisation, 2196 alteplase-eligible patients with acute ischaemic stroke were included: 1081 in the intensive group and 1115 in the guideline group, with 1466 (67·4%) administered a standard dose among the 2175 actually given intravenous alteplase. Median time from stroke onset to randomisation was 3·3 h (IQR 2·6-4·1). Mean systolic blood pressure over 24 h was 144·3 mm Hg (SD 10·2) in the intensive group and 149·8 mm Hg (12·0) in the guideline group (p<0·0001). Primary outcome data were available for 1072 patients in the intensive group and 1108 in the guideline group. Functional status (mRS score distribution) at 90 days did not differ between groups (unadjusted odds ratio [OR] 1·01, 95% CI 0·87-1·17, p=0·8702). Fewer patients in the intensive group (160 [14·8%] of 1081) than in the guideline group (209 [18·7%] of 1115) had any intracranial haemorrhage (OR 0·75, 0·60-0·94, p=0·0137). The number of patients with any serious adverse event did not differ significantly between the intensive group (210 [19·4%] of 1081) and the guideline group (245 [22·0%] of 1115; OR 0·86, 0·70-1·05, p=0·1412). There was no evidence of an interaction of intensive blood pressure lowering with dose (low vs standard) of alteplase with regard to the primary outcome. Although intensive blood pressure lowering is safe, the observed reduction in intracranial haemorrhage did not lead to improved clinical outcome compared with guideline treatment. These results might not support a major shift towards this treatment being applied in those receiving alteplase for mild-to-moderate acute ischaemic stroke. Further research is required to define the underlying mechanisms of benefit and harm resulting from early intensive blood pressure lowering in this patient group. National Health and Medical Research Council of Australia; UK Stroke Association; Ministry of Health and the National Council for Scientific and Technological Development of Brazil; Ministry for Health, Welfare, and Family Affairs of South Korea; Takeda.

7 September 2017 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
PEPaolo Eusebi
Paolo Eusebi
DGDavid Giannandrea
David Giannandrea
LBLeonardo Biscetti
Leonardo Biscetti
IAIosief Abraha
Iosief Abraha
DCDavide Chiasserini
Davide Chiasserini
Parnetti LucillaParnetti Lucilla
Parnetti Lucilla

5 April 2011 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
Parnetti LucillaParnetti Lucilla
Parnetti Lucilla
DCDavide Chiasserini
Davide Chiasserini
GBGianni Bellomo
Gianni Bellomo
DGDavid Giannandrea
David Giannandrea
CCClaudia De Carlo
Claudia De Carlo
OEOmar El-Agnaf
Omar El-Agnaf

1 December 2018 in The Lancet Neurology
Verified
Journal Article
Closed access
SKScott E Kasner
Scott E Kasner
BSBalakumar Swaminathan
Balakumar Swaminathan
PLPablo Lavados
Pablo Lavados
MSMukul Sharma
Mukul Sharma
KMKeith Muir
Keith Muir
JZJ Zwiernik
J Zwiernik

31 March 2014 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
PDF file
Parnetti LucillaParnetti Lucilla
Parnetti Lucilla
LFLucia Farotti
Lucia Farotti
PEPaolo Eusebi
Paolo Eusebi
DCDavide Chiasserini
Davide Chiasserini
CCClaudia De Carlo
Claudia De Carlo
PCPaolo Calabresi
Paolo Calabresi
There is a great interest in developing cerebrospinal fluid (CSF) biomarkers for diagnosis and prognosis of Parkinson's disease (PD). CSF alpha synuclein (α-syn) species, namely total and oligomeric α-syn (t-α-syn and o-α-syn), have shown to be of help for PD diagnosis. Preliminary evidences show that the combination of CSF t-α-syn and classical Alzheimer's disease (AD) biomarkers—β-amyloid 1–42 (Aβ42), total tau (t-tau), phosphorylated tau (p-tau)—differentiate PD patients from controls, and that reduced levels of Aβ42 represent a predictive factor for development of cognitive deterioration in PD. In this prospective study carried out in 44 PD patients and 25 neurological controls we wanted to verify whether the combination of CSF α-synuclein species—t-α-syn and o-α-syn—and classical AD biomarkers may help in differentiating PD from neurological controls, and if these biomarkers may predict cognitive decline. The median of follow-up duration was 3 years (range: 2–6 years). Mini Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) were used for monitoring cognitive changes along time, being administered once a year. Oligo/total α-syn ratio (o/t-α-syn ratio) confirmed its diagnostic value, significantly contributing to the discrimination of PD from neurological controls. A greater diagnostic accuracy was reached when combining o/t-α-syn and Aβ42/tau ratios (Sens = 0.70, Spec = 0.84, AUC = 0.82; PPV = 0.89, NPV = 0.62, LR+ = 4.40, DOR = 12.52). Low CSF Aβ42 level was associated with a higher rate of MMSE and MoCA decline, confirming its role as independent predictive factor for cognitive decline in PD. None of the other biomarkers assessed (t-tau, p-tau, t-α-syn and o-α-syn) showed to have prognostic value. We conclude that combination of CSF o/t-α-syn and Aβ42/tau ratios improve the diagnostic accuracy of PD. PD patients showing low CSF Aβ42 levels at baseline are more prone to develop cognitive decline.

2 March 2012 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PDF file
Parnetti LucillaParnetti Lucilla
Parnetti Lucilla
DCDavide Chiasserini
Davide Chiasserini
PEPaolo Eusebi
Paolo Eusebi
DGDavid Giannandrea
David Giannandrea
GBGianni Bellomo
Gianni Bellomo
PCPaolo Calabresi
Paolo Calabresi
Mild cognitive impairment (MCI) is a common condition in the elderly which may remain stable along time (MCI-MCI) or evolve into Alzheimer's disease (MCI-AD) or other dementias. Cerebrospinal fluid (CSF) classical biomarkers, i.e., amyloid-β 1-42 (Aβ